Podcasts about Blue Earth

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Join us for an open and honest conversation with Will Hayler, Co-Founder and CEO of Blue Earth Summit, as he shares his journey from teaching surfing in Cornwall to leading one of the most innovative sustainability platforms in the business world. Key moments in this episode: How Will built his first business, Tickets to Ride, from surf lessons to a global adventure sports company The art (or not!) of business acquisitions and mergers in your 20s Creating Blue Earth Summit and its mission to transform how the world works Balancing entrepreneurship with family life and surfing Leadership insights on building and managing successful teams Will shares candid insights about: The relationship between the outdoor industry and sustainability Building purpose-driven businesses The future of sustainable innovation If you enjoy this or any of our episodes, please hit the follow button on your podcast platform of choice. Follow Will Hayler https://www.linkedin.com/in/willhayler/ Follow Dan Trapp https://www.linkedin.com/in/dantrapp Follow Sports + Outdoor Mentors https://bit.ly/SOMentors_Linkedin Watch Sports + Outdoor Mentors https://www.youtube.com/@S_OM1 #sportsandoutdoormentors

In May 1980, a woman's body was found near Blue Earth, Minnesota. In 2015, the woman was identified as 18-year-old Michelle Yvette Busha, who had been buried in an anonymous grave for nearly 35 years. Join Mike and Gibby as they discuss the murder of Michelle Busha. In 1988, a former Minnesota State Trooper named Robert Leroy Nelson confessed to a litany of crimes. One of these crimes was an unsolved murder that Nelson said he committed in Minnesota while on duty. The details of his confession, as well as his former occupation, shocked people.You can help support the show at patreon.com/truecrimeallthetimeVisit the show's website at truecrimeallthetime.com for contact, merchandise, and donation informationAn Emash Digital productionSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is the second episode from the Blue Earth Summit 2024. Please check out our instagram feed @fortheloveofweather to get a flavour of what we got up to.We captured and shared as many speakers and guests as we could and yet again we were blown away by the amazing conversations we had and most importantly people's willingness to give us their time to talk about what they were passionate about.The Blue Earth Summit is held over 3 days and plays host to 5,000+ decision makers, industry pioneers, provocative thought leaders, sustainability trailblazers, insightful solutions and boundary-pushing start ups. It's the place to explore, meet, learn, collaborate and take action.In this episode of the podcast we speak to Avery Johnston from KPMG, Blue Earth Summit co-founder Linley Lewis, Ben Pollack from Climate Cartographic and interviewer Hannah MacInnes. Avery Johnstone is a manager in KPMG's Global Decarbonisation Hub. KPMG are doing work around story telling to bridge the gap between the decision makers in big business today and young people that are going to inherit those roles in the future. Avery has a powerful ethos about business and climate change. She says that that you don't have to be a full time activist to impact change. People can use their autonomy, skill and education to make a difference - ‘Mobilising everyone is what we need'. You can find Avery Johnstone on LinkedIn. Linley Lewis COO & Co-Founder of the Blue Earth Summit. Linley and the founders saw an opportunity to bring his love of the outdoors and sustainable business and co-created the Blue Earth Summit. Linley talks a little about climate fatigue and how the Blue Earth Summit is designed to inspire and connect through motivational speaking while creating a space for sustainable business, start up's and philanthropy. You can find Linley on LinkedIn. Our third guest is Ben Pollack a Co-Founder & Strategy Director of Climate Cartographics. Ben felt he needed a change in his career and drew on his love of the outdoors to harness his data skills to develop impactful visualisations of ecology and the environment. His business offers a design service for companies wanting to make impactful visualisations through using 3D modelling. Check out their website climatecartographis.com to find examples of their work. Ben is also on LinkedIn. Our final guest is Hannah MacInnes an interviewer at the Blue Earth Summit. Hannah talks about how important it is for all ages to be represented in climate from very young to very old. She remarks on the changing nature of audiences, mainly with audiences becoming younger but that we can still learn from older members of society and how it is deeply engrained in them to live within their means while having a huge respect for nature. You can find Hannah MacInnes at @hannahmacin.

Blue Earth county results, Pete Stauber, state results, Tim Walz exposed, Jimmy Kimmel,  the market responds, Candi from DOA, Chris from Acrisure, what RFKj would do, nothing but a good time, and more...See omnystudio.com/listener for privacy information.

We were thrilled to return to the Blue Earth Summit 2024 this time in London. Please check out our instagram feed @fortheloveofweather to get a flavour of what we got up to. We captured and shared as many speakers and guests as we could and yet again we were blown away by the amazing conversations we had and most importantly people's willingness to give us their time to talk about what they were passionate about.The Blue Earth Summit is held over 3 days and plays host to 5,000+ decision makers, industry pioneers, provocative thought-leaders, sustainability trailblazers, insightful solutionists and boundary-pushing start ups. It's the place to explore, meet, learn, collaborate and take action.In this episode of the podcast we speak to three inspiring individuals.Nicole van der Velden - Sailor for the Spain SailGP team Gemma Metheringham - PhD student and found of @the_elephant_in_my_wardrobeCoco Peuscet - Marketing manager at Reskinned. Our first guest is Nicole van der Velden, who is a Spanish-Aruban sailor. She tells us all about SailGP. Not only are they reducing their carbon footprint, but they are pushing boundaries in gender equality in sailing. If you have never seen SailGP, it is like formula 1 but on water. It is such an exciting sport and it was a geniune joy to talk to Nicole. Her enthusiasm is infectious! You can find Nicole on socials at @nicolevelden. Our second gues is Gemma Metheringham aka @the_elephant_in_my_wardrobe . She is now a PhD student at Nottinham Trent and her passion is to understand whether the growing second hand market can be a lever that decarbonises mainstream fashion. Gemma talks us through the psychology and value we place on second hand clothes. It really was a fascinating chat about what the term 'valuable' means. How do we feel about clothes if we know the story behind them or if we can see and try them on versus buying on line. Gemma was inspiring and thought provoking and we can't wait to see how this journey goes for her. Our final conversation in this podcast is with Coco Peuscet, who is the marketing manager at 'Reskinned'. This conversation absolutely got our heads in a spin! If you didn't know anything about new fashion, your jaw will drop when you find out what happens to most of the clothes that we send back to our well known brands. Although Coco sees the reality of what happens to clothes we send back she was full of top tips and really useful information that is easy for all of us to do. Small things all add up to make a big difference. You can find Coco Peuscet on LinkedIn

A story of a monster buck on the bluffs of the Blue Earth river

Blue Earth Capital, a specialist global impact investor, is making waves in the world of impact investing by pioneering impact secondaries among other strategies. As Managing Director and Head of Private Equity Partnerships at BlueEarth, Nicolas Muller is focused on delivering social and environmental impact combined with market-rate returns.In this episode, Nicolas shares how BlueEarth isn't just talking about change—they're making it happen. Under his leadership, his team has built a powerful portfolio, with notable investments including  African FinTechs, an EdTech in the US, in innovative bioagriculture companies, and a Ukrainian gender-smart strategy to support quality jobs. With over $1.2 billion in assets under management, BlueEarth is globally impacting both developed and emerging markets.To discover how BlueEarth is not just investing in the future but actively building it, one investment at a time, tune in as Daniel dives into how BlueEarth is making a real difference in impact investing by combining profit with purpose.

6-25 Adam and Jordana 11a hour

Hour 1: Jason talks with Sen. Nick Frentz & Sen. Rich Draheim from Blue Earth county about the flooding in Mankato. Then he's joined by Dr. Todd Stanhope from North Memorial about why they're reducing birth services at North Memorial 

The county says the rain-swollen Blue Earth River has cut around the west side of the dam and there are concerns about debris in the river. Authorities are notifying residents downstream of the dam.MPR News senior reporter Hannah Yang was on the scene and told us what was happening.

Minnesota's Department of Commerce announced a settlement with UnitedHealthcare today over the company's alleged violation of mental health parity laws. And a Blue Earth man pleaded guilty today to participating in the January 6th assault on the U.S. Capitol.Those stories and more in today's evening update from MPR News. Hosted by Emily Reese. Music by Gary Meister.

Matt reminisces on a favorite memory; Michael Cohen testimony continues; Red Lobster closings; the old flag guys; Patrick Coolican has his Tuesday interview with Brett; Glenn Gruenhagen; Itasca County Jail has Ten Commandments painted over; Blue Earth man pleads gulity in Capitol insurrection.

Today Trae sits with Brodrick Ryans, the Director of "Brown Bodies on a Blue Earth". He shares his pathway into theater and directing while also discussing what the audience can expect out of this show. Next, Trae talks with Arlene Hampton, a Community Advocate, about her inspiration to do the work she does in community and why it's important.

Today Trae connects with Cris Blak, the Playwright for "Brown Bodies on a Blue Earth". He shares his inspiration for the show and his partnership with The Underground Theatre to bring it to the main stage. Next, Trae talks with Kweli Vuur. She shares her journey as a poet, and her upcoming A Woman is Healing event for Mother's Day.

Tyler @JTyPatrick& James @SupermanRed_Kr Review comics and Justice League Action. #Superman  #DCComics @DCOfficalFor all things Krypton Report: https://linktr.ee/KryptonreportOur new TEE Public Store: http://tee.pub/lic/gJJ3wcW9NCEHelp keep Krypton from Exploding join the $1 a month Patreon: https://www.patreon.com/kryptonreportpod

History is all around us in Blue Earth County and no one knows that better than Jessica Potter, Executive Director of the Blue Earth County Historical Society. From artifacts and articles to events and a museum, her days are filled with the past, present and future of the Minnesota River Valley. Hear her today on the podcast, talk about the work her organization does to preserve our past and what's ahead for the museum and its contents. Website: https://blueearthcountyhistory.com/ Facebook: https://www.facebook.com/bechshistory

#508 Tyler @JTyPatrick& James @SupermanRed_Kr Reviewcomics and Justice League Action. #Superman  #DCComics @DCOffical   For all things Krypton Report: https://linktr.ee/Kryptonreport   Our new TEE Public Store: http://tee.pub/lic/gJJ3wcW9NCE   Help keep Krypton from Exploding join the $1 a month Patreon: https://www.patreon.com/kryptonreportpod    

We're back! And so is Philip Kennedy Johnson! We sit down with PKJ for the second time to talk about his recently wrapped runs on Action Comics & Alien. Listen now! Intro Apologies for delay in episodes - see blog post for more PKJ Last time we spoke was Feb. 2021, discussing Last Sons of America, Kill A Man and end of The Last God Superman (3:42) What was something you wanted to do with Superman that hadn't been done before? Exploration of Clark-Jon relationship - so many emotional moments Warworld Saga - why go with Mongul for main villain of storyline? Love Osul and Otho - their lack of exposure to anything resembling compassion and love, and the welcoming by the Superman family, is best addition to mythos in a long time Superman family gets major focus here - family is thru-line running across the entire arc Special point on Kong Kenan and his “defection” Blue Earth movement - *chef's kiss* Alien (22:28) Another instance of a father doing anything for his son in first arc Was it always the plan to have 3 separate arcs across 2 volumes? How much input did you have into Xenomorph designs, or was that all artists? Ending (34:00) Next episodes: Speedball, Deathstroke Plugs for social GonnaGeek Network Apple Podcasts: here Google Play: here Stitcher: here TuneIn: here iHeartRadio: here Twitter Facebook Patreon TeePublic Discord  

We took the podcast to the Blue Earth Summit 2023 in Bristol. Please check out our instagram feed @fortheloveofweather to get a flavour of what we got up to. We captured and shared as many speakers and guests as we could! We were absolutely blown away by the amazing talks and conversations we had and most importantly people's willingness to give us their time to talk about what they were passionate about. The Blue Earth Summit is held over 3 days where Bristol plays host to 5,000+ decision makers, industry pioneers, provocative thought-leaders, sustainability trailblazers, insightful solutionists and boundary-pushing start ups. It's the place to explore, meet, learn, collaborate and take action.FYI The Blue Earth Summit was incredibly busy! There is back ground noise but hopefully you will take away something from the mini podcasts we managed to record. ——————————Our first guest.Meet Emma Askew @Emmaaskewuk, founder of @Earthminutesuk . Their mission is to drive the future of environmental learning and thinking, making it accessible to everyone but also sharing it in a way that is sustainable. Emma was quite simply so inspiring to talk to. She is from the soil science sector which she said was a really important inflection point for her. This is where she realised there was a huge gap between the science she was working in and the communications of the science.Emma speaks so passionately about encouraging young people into leadership early and building a connection with the environment from a young age. She says she has hope for the future and community is where hope grows through community action. ——————————Our second guest.Michael Cunningham is the founder of the 9trees Community Interest Company, founded in 2018. Michael was originally involved in conservation and observed that while he was completing a lot of work, woodlands were changing rapidly and not all conservation work was having positive impact. Michael decided he wanted to do something about this. He worked out that each individual in the UK roughly emits 9 tonnes of carbon into the atmosphere annually. Each tree (based on a hectare of woodland) sequesters 1 tonne of carbon over the lifecycle of any one tree and so 9trees was born. Individuals or businesses can sponsor trees to create woodlands or nature reserves that you can visit today and watch flourish over time. Michael describes this as watching hope grow. So far the company has planted 15,000 trees but they plan to plant 10,000 trees every year over the next few years and in every county in the UK with Northern Ireland being the next country to plant in. You can find Michael's company at https://www.9trees.org and on instagram @9treesuk —————————Our final guestMeet Sandra - chair of the West Bristol climate action group. Sandra talks about how small local changes are very important nationally. She wants to create wildlife corridors locally and between other towns. Sandra's message is that decarbonising in small ways adds up to large changes. You can find Sandra at http://www.westbristolclimateaction.org

What is 55 feet tall, wears size 78 shoes, weighs 8,000 pounds, is green head-to-toe and lives in Blue Earth? Did you guess the Jolly Green Giant statue? The colossus has made a home in Southern Minnesota since 1978. But how did he get there? And who came up with the idea for the Jolly Green Giant? MPR contributors Robbie Mitchem, Jamal Allen, and Britt Aamodt tracked down his backstory for this installment of our history series, Minnesota Now and Then.

School resource officers (SROs) are set to return to two districts in Blue Earth County.This comes about a week after Attorney General Keith Ellison released a second opinion meant to clarify when officers are allowed to use force, including certain kinds of restraints, under a new law.A number of law enforcement agencies across the state have recently pulled officers from schools, saying they needed more clarity. And they called for a special session to revise the law. 'We're all clear' Ellison says latest moves should end questions over police in schools The Minnesota Police and Peace Officers Association sent a letter to its members agreeing to Ellison's updated guidance. Blue Earth County Sheriff Jeff Wersal told MPR News reporter Tim Nelson he is following that advice. “Every case is different, every case is unique. So as long as the deputy can articulate the need for force — once POST [Board] weighed in and MPPOA weighed in — I felt comfortable putting them back in,” he said. “I still feel, though, that it needs to be looked at by the legislature.”The Blue Earth County Sheriff's office oversees the deputies that work in St. Clair and Lake Crystal Wellcome Memorial School District, which have about 760 and 960 students respectively. Mankato Area Public Schools is by far the largest district in Blue Earth County, and that city's Public Safety Department also pulled its SROs over the law.A school district spokesperson told MPR News the city is waiting for guidance from the League of Minnesota Cities, expected sometime this week.St. Clair Superintendent Tim Collins and Lake Crystal Superintendent Mark Westerburg joined MPR News host Cathy Wurzer to talk about the decision to reinstate SROs.Use the audio player above to listen to the full conversation.Subscribe to the Minnesota Now podcast on Apple Podcasts, Google Podcasts, Spotify or wherever you get your podcasts.We attempt to make transcripts for Minnesota Now available the next business day after a broadcast. When ready they will appear here.

We've finally gotten round to finishing our ongoing anime series Project Blue Earth SOS, and boy is this a jam-packed episode. The stakes are high as the alien invaders have earth in their grasp, and there are a whole host of mysteries to be answered. Will this episode answer them all? Is this the best episode of the bunch? Should this series have been way shorter? Tune in to find out!Sam has also been reading Mike Mignola's comic classic Hellboy, watched both Guillermo Del Toro Hellboy movies & started the Guardians of the Galaxy video game. Meanwhile Lewis has been rewatching sitcom classics Friends & The Office (US).00:00 Intro & Catchup01:55 Project News (Upcoming Marvel Stuff)18:55 Project Blue Earth SOS (2006) "Super-Weapon Sortie! Battle at Earth's Final Hour!"01:23:33 Personal Projects (Hellboy comics, Hellboy (2004), Hellboy: The Golden Army, Friends, The Office (US) & Guardians of the Galaxy the game).Thanks to Karl Casey @ White Bat Audio for the synths.Contact us:https://linktr.ee/theprojectprojectpod

In honor of the 459th anniversary of the birth of William Shakespeare, we have a little history nugget for you. There are surprising historical connections to be gleaned from small-town graveyards. MPR News Host Cathy Wurzer talked with Faribault County Historical Society Executive Director Randy Anderson about the link between one of the great Shakespearean actresses of the London stage in the early 1800s and the town of Blue Earth in southern Minnesota.

We recap game vs. Blue Earth and preview sub section Championship vs. LCWM!

We recap playoff game vs. Medford preview Blue Earth matchup and talk about the playoffs.

This week we revisit the world of Project Blue Earth SOS, hoping that the alien invasion will finally kick into gear. Will the invaders do anything substantial this episode? Will our heroes figure out what's going on? Will we continue to be frustrated by this series? Tune in to find out.We've also finished Disney+ super-comedy Extraordinary and discuss the last 2 episodes, whilst Lewis has watched Oscar-nominee The Banshees of Inisherin, Predator-sequel Prey and Attenborough's Life in Colour. Meanwhile Sam watched 2017 British horror The Ritual.We also discuss James Gunn's new slate of DCU films including Creature Commandos,  Superman: Legacy & new Batman entry The Brave and the Bold. Lewis also opens our first on-pod gift!00:00 Intro & Catchup (DCU Slate & Lewis Opens A Gift)24:23 Project News (EA's Iron Man Game)27:56 Project Blue Earth SOS (2006) "Extreme Offense, Extreme Defense! Solving the Mystery of Element X!"01:10:22 Personal Projects (Extraordinary, The Banshees of Inisherin, The Ritual, Prey & Attenborough's Life in Colour)Thanks to Karl Casey @ White Bat Audio for the synths.Contact us:https://linktr.ee/theprojectprojectpod

On May 26, 1980, an 18-year-old runaway was picked up by a state trooper in Minnesota, who viciously raped and murdered her while on duty. Her body was discovered about a week later and her remains were ultimately buried as an unidentified person. In 1989, her murderer confessed but sadly, she would still not be identified until 2015, when DNA was finally confirmed. This is the story of Michelle Busha.Toronto Rape Crisis Centre/ Multicultural Women Against Rape |https://trccmwar.caCall 416-597-8808 for support on their 24-hour crisis line.Patreon |https://www.patreon.com/Femicide_PodcastFollow |@femicide_podcast on Instagram https://www.instagram.com/femicide_podcast/ @femicidepodcast on Facebook https://www.facebook.com/femicidepodcastHome Studio Equipment Used | Affiliate LinksBlue Yeti USB Microphone | https://amzn.to/2ShOMcrFoam Windscreen cover | https://amzn.to/38nriZaPop Filter | https://amzn.to/2Sjeu0vAcoustic Absorption Panel | https://amzn.to/39thLjcApple MacBook Pro | https://amzn.to/2OJip4cMusic credits |Ice flow musicMusic from https://filmmusic.io"Ice Flow" by Kevin MacLeod (https://incompetech.com) License: CC BY (http://creativecommons.org/licenses/by/4.0/)Welcome to horrorland musicMusic from https://filmmusic.io"Welcome To Horrorland" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Information sources |https://en.wikipedia.org/wiki/Murder_of_Michelle_Bushahttps://www.usatoday.com/story/news/nation/2015/07/16/missing-texas-girl-mystery-solved/30254607/https://truecrimereport.news.blog/2020/10/28/the-murder-of-michelle-busha/https://en.wikipedia.org/wiki/Bay_City,_Texashttps://www.policeprostitutionandpolitics.com/pdfs_all/COPS%20RAPE%20SEX%20ASSAULTS%20ADULTS%20NON%20PROST/1980%20Robert%20Leroy%20Nelson%20%7C%20State%20Trooper%20Minnesota/35%20years%20later,%20woman%20slain%20by%20state%20trooper%20in%20southern%20Minnesota%20is%20ID'd%20%7c%20Star%20Tribune.pdfhttps://en.wikipedia.org/wiki/Blue_Earth,_MinnesotaSupport the showPatreon |https://www.patreon.com/Femicide_PodcastFollow |@femicide_podcast on Instagram https://www.instagram.com/femicide_podcast/ @femicidepodcast on Facebook https://www.facebook.com/femicidepodcast

Greater Mankato Growth is announcing the winners of their first round of recipients for the Main Street Revitalization Grants. Ryan Vesey, Economic Development & Research Manager from Greater GMG is our guest on the podcast today. Ryan is reviewing the award winners and talking about how to qualify for the next round of grants. Businesses seeking to develop or redevelop property in Blue Earth and Nicollet County can apply for grants to cover up to 30% of the total eligible project costs. Target corridors include the Mankato and North Mankato City Center, the US Hwy 60/169 corridor, and the US Hwy 14 corridor. Corridors are visible on this map: MN Main Street - Greater Mankato Commercial Corridors. The grant application as well as application instructions and frequently asked questions are available here. The deadline for application submissions is Tuesday, January 31.

BLUE EARTH BAGS WITH JJC by 101.9POR

The Rev. Matthew Lorfeld, pastor of St. Paul and Immanuel Lutheran Churches in Blue Earth, MN, joins the Rev. Dr. Phil Booe to study Exodus 5. Moses and Aaron, obeyed YHWH, the one true God, and went to Pharaoh and commanded, “Let my people go!” For those who know, this will be merely the first of many times Moses will demand the Egyptian king release the Hebrew people. Pharaoh refuses, but his reasoning will prove to be vital to understanding what happens next. He proclaims, “Who is YHWH that I should obey his voice?” YHWH will, over time, show Pharaoh just who he is. It's the true story of God reaching down into history and, through an unlikely prophet, redeeming his chosen people from slavery. It's the story of Exodus, but it's also the story of us all. How through Christ, God has liberated us from sin, death, and the Devil. Don't miss this chapter-by-chapter study of the Book of Exodus on Thy Strong Word.

This week we return to the world of Project Blue Earth SOS with the 4th episode of this alien invasion anime, which manages to cover both space rescue and ghost hunting!Join us as we discuss the slow-moving plot, the ever-changing tone & and the seemingly never-ending mystery boxes.Sam has also been watching Guillermo del Toro's Cabinet of Curiosities & Big Mouth Season 6, whilst Lewis has been watching Star Wars: Tales of the Jedi & Choose or Die.00:00 Intro & Catchup02:40 Project News (Eden Project Guy Upset, Serkis Does Silmarillion, New Villa Manager & Twitter Truth At Risk)13:26 Project Blue Earth SOS (2006) "The Aliens' Trap! 'Invincible' Responds!"Personal Projects (Guillermo del Toro's Cabinet of Curiosities, Big Mouth Season 6, Star Wars: Tales of the Jedi & Choose or Die)Contact us:https://linktr.ee/theprojectprojectpod

We Recap the playoff game vs. New Richland and preview rematch vs. Blue Earth.

Pastor, St. John Vianney - Fairmont and Sts. Peter & Paul in Blue Earth

Deacon at St. John Vianney - Fairmont and Sts. Peter & Paul in Blue Earth, Founder of Fairmont Area Catholic Radio

This week the Wonderspace podcast is capturing stories of hopefulness at the Blue Earth summit in Bristol. For three days hundreds of makers and mavericks, founders and activists, adventurers and investors came together with a collective desire to see business as a force for good in protecting our planet and all people. So sit back and enjoy this 25 minute fix of hopefulness featuring 46 people at the Blue Earth Summit and think about the person or organisation you would like to promote on our web site www.ourwonder.space More information: www.blueearthsummit.com To view the episode page with a summary of the interview, links to social media and projects mentioned, go to https://ourwonder.space/episodes/_86

In this Bonus Episode we share our interview with the Blue Earth Summit Podcast. Remember nothing in this podcast is financial advice and when investing your capital is at riskTheir show notes: Summary Tom McGillycuddy and Matt Latham, Co-Founders of CIRCA5000 tell us how and why we should consider investing in sustainable businesses. Description“If you were trying to find the perfect company to invest in, you'd never make a single decision. There are always trade offs.”Tom McGillycuddy and Matt Latham are Co-Founders of CIRCA5000, an impact investing app based in the UK. The pair created the app to make it easier for people to put their money into sustainable businesses, without it costing the earth and say they're banking on a future that humanity features in.The pair tell host Laura Nesbitt why everyone should care where they're investing their money, they share their top tips on how beginner investors can get started and explain why CIRCA5000 gaining B Corp status was a huge milestone for their company. Links Follow CIRCA5000 on Twitter.Find out more at www.blueearthsummit.com Follow Blue Earth Summit on Twitter Follow Blue Earth Summit on InstagramFollow Laura on InstagramWhat is the Blue Earth Summit?Blue Earth Summit is a movement. A dynamic mix of communities, redefining how we work and driven by a love for the outdoors. A new way to connect and regenerate our connection to our blue earth.With our eclectic Bristol venue partners the Marble Factory and The Wave, October 2022 will see an extended programme over three days. Two days of inspirational content in central Bristol followed by a final day of activity-led networking at one of Europe's premier sporting venues.Buy tickets here." Hosted on Acast. See acast.com/privacy for more information.

Scott Haase farms in Blue Earth, Minnesota, raising crops with his brother Brent and raising pasture and woodland pork under Blue Dirt Farm. Their German ancestors “walked here from Wisconsin back in the 1860's,” and they still farm some of the land where those ancestors homesteaded. Like most in the area, the Haase family farm is still a fairly conventional corn and soybeans farm. They have made some changes, including going completely no-till on their soybeans and reducing tillage overall, and adding cover crops to their management. The soil in the region feels difficult to manage for most, but Scott thinks “tillage here just begets more tillage” and the transition has been worth it. In his conversation with host Jared Luhman, Scott discusses the challenges and joys of raising Mangalitsa pigs on pasture, including pasture rotation, marketing, inventory management, processing, and fencing technology. He has long range goals for the land, and is mindful of the risk of burnout. “It's very hard and you need support from customers and the community at large” he says, reflecting on the value of farmer-to-farmer relationships and knowledge that he's built through SFA and other networks. His passion and self-admitted stubbornness keep him moving forward: “I really want to make an impact on more land than just my own farm…I've really gotten excited about finding things that work on the land and sharing those with people and providing really high-quality products.”   Scott Haase, Blue Dirt Farm Jared Luhman, Soil Health Lead, SFA   Cannon Valley Butcher's Block The Meatery   If you've enjoyed this podcast, please consider supporting Dirt Rich and SFA's work by donating or becoming a member at www.sfa-mn.org. The viewpoints of the speakers expressed within or outside of this episode do not necessarily reflect the goals and mission of SFA. Dirt Rich is produced by the Sustainable Farming Association.

We break down the come from behind victory over Central Norwood Young America, preview the big homecoming game vs Blue Earth, and talk Maple River Football.

Barb Kaus is the CEO of the Greater Mankato Area United Way. Today we're talking about the United Way's impact on the community, the annual capital fundraising campaign, and how you can get involved. The United Way serves 55 programs within 38 agencies in the 4 county areas of Blue Earth, Nicollet, LeSueur and Waseca.

Let's talk trash on this episode. No, really. And why you should think more about your garbage. When it comes to throwing our food away, and I don't mean to offend anyone here, but most of us just toss it in the garbage. Or maybe we put it in the sink disposal and grind it up. But throwing it away is bad. Why? Well, we're about to find out…   Alexander Williams is the owner & the director of operations at Blue Earth Compost. After purchasing the fledgling business in April 2014, Alex has grown the company into a full-service food scrap collection business with 12 employees and approximately 2,000 customers. In 2017, in recognition of his efforts to solve the food waste crisis, Alex received the Northeast Recycling Council's Environmental Sustainability Leadership Award – Young Professional. That's no easy feat.   I know I learned a thing or two from this episode about food waste, and I hope you will too…

Welcome back to Word of God! We are: Ash (the old-time fan), Emma (the latecomer), and Wyatt (the newbie). We're digesting this show in chunks of about two episodes a week. Welcome to season five! Today we talk about Episode 46: 5.17 "99 Problems" and 5.18 "Point of No Return." Remember, the finale's coming soon, so send us your questions for the post-mortem of Kripke era! Show Notes (also here on tumblr): Content warnings for this episode are HERE Sources for references made this episode: the Jolly Green Giant statue in Blue Earth, MN the reason they couldn't have a beach episode, by @outdean Ash's doodle of Cas at the beach John's least favorite post, by @godsquad Zach's wings shot There were a couple more images set aside to be linked, but something went wrong and we're not sure what the pictures were anymore. Sorry! Check our Listen page or go to our Pinned post on tumblr to find a list of platforms you can find us on - don't forget to rate and review if you can! The music for Word of God is The Last Ones by Jahzzar from freemusicarchive.org, licensed under Attribution share-alike 3.0 international license. Find the song HERE Have any questions or comments? Email us at wordofgodcast@gmail.com, tweet us, or send us an ask on tumblr!

We are back!In this episode the guys sit down with Nesta OG and get into his upbringing and what got him into music. The talk about his early years as an artist, his upcoming project titled, "blue Earth Theory". They discuss his journey in journalism, how and why he started the Weather Watcher and his plans for the future. The guys review LaRusell and how prolific he's been n the last 18 months. They close the episode out with an unreleased track from Nesta OG titled, "Missed Call" -INSTAGRAM- Nesta OG-https://www.instagram.com/nestaog/The Rap Dad Podcast- https://www.instagram.com/therapdadpodcast/Junes-https://www.instagram.com/renojunes/Melancholy-https://www.instagram.com/melancholy775/-SPOTIFY-Nesta OG-https://open.spotify.com/artist/2QBxcLG1PNMzK6pHe9s78f?si=c4CxG0kkQ-eTZj4JzHKayQJUNES-https://open.spotify.com/artist/3lQ3YYjLBvhAS0wAbmzmrN?si=g3hWch54TGCcxry_UeSVBAMelancholy-https://open.spotify.com/artist/1KureyR6SSmc9aTvGUNPB0?si=Pl1jGFW-Rdy7xBNOmlqoiQRap Dad Playlist-https://open.spotify.com/playlist/6ba8703i8SShY66s7lv8xx?si=13af9e5b8fd347f9YOUTUBENesta OG-https://www.youtube.com/results?search_query=Nesta+OGJunes-https://www.youtube.com/channel/UCDufibhBgmnsYu-tpZY3BwQ

Kirsty & Carissa dive into this translation of Lebanese poetry to discuss the blending of various traditions, legends, and truths.   Topic: A Handful of Blue Earth by Vénus Khoury-Ghata Theme: "Make It Ours" by Evermore

One Earth, Two Earth, Red Earth, Blue Earth. It's yet another bonus episode with Chamar and Andrew for the final stop on our ride Across the DC-Verse!! In the multiverse crossover film, https://en.wikipedia.org/wiki/Justice_League:_Crisis_on_Two_Earths (Justice League: Crisis on Two Earths), the Justice League travel to a different version of their earth and come face to face with their evil reflections. As always, we are here to ask the big questions: Does the story make sense? How does it compare to the comic? Is it a good addition to the universe? And most importantly, does having a mafioso accent make you qualified to run an evil Justice League? Also, rate and follow Yet Another DC Animated Podcast on https://linktr.ee/yadcanimatedpod (social media) or check us out at https://www.forgottenentertainment.com/yet-another-dc-animated-podcast (Forgotten Entertainment).

Project Blue Earth SOS is back with a vengeance! The alien invasion is picking up pace as our heroes are forced to confront ghosts from their past in our darkest chapter yet. Our ongoing anime recap continues with this exciting episode which features Zombies, Aurora Borealis and whatever the hell 'Angel Hair' is. Sam has been on an Adam Scott marathon with Parks & Rec and Severance, whilst Lewis has been rewatching Agents of SHIELD and Eurovision.00:00 Intro & Catchup02:41 Project News (MCR Return & Lazarus Project)10:13 Project Blue Earth SOS "The Invaders and Their Evil Powers Firing Up the G-Reaction Engine!"01:04:25 Personal Projects (Parks & Rec, Severance, Agents of SHIELD & Eurovision)Contact us:https://linktr.ee/theprojectprojectpod

On May 9th, 1980, Michelle Busha is reported missing. On May 26th, she is murdered at the age of 18 and found in a ditch off Interstate 90 in Blue Earth, Minnesota. It took 8 years to find her killer and 35 years to identify her body and to bring closure to Michelle's family. Facebook: Horrific Heartland Podcast Discussion GroupInstagram: horrificheartlandpodcastTikTok: horrificheartlandpodcasthorrificheartland@gmail.comSources:https://www.cbsnews.com/news/minnesota-troopers-murder-victim-identified-35-years-later/https://www.fox9.com/news/explainer-how-jane-doe-was-identified-as-michelle-busha-35-years-laterPress Conference: https://www.youtube.com/watch?time_continue=134&v=O8Tw4FGOJJg&feature=emb_titlehttps://www.twincities.com/2015/03/16/minnesota-troopers-1980-murder-victim-is-idd-thanks-to-dna/

In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu.Contributors: Dr Morgans has disclosed that she has received funds for research support from Atellas, AstraZeneca, Bayer, Myovant, and Pfizer, and consulting fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Janssen, Lantheus, Merck, Myovant, Novartis, Pfizer, Sanofi, and Telix.Ms Martone has no relevant conflicts of interest to report. 

This episode is also available as a blog post: https://marionmarchetto.wordpress.com/2021/07/31/blue-earth-by-dawn-o-watson-book-review/